Home » Stocks » BiomX

BiomX, Inc. (PHGE)

Stock Price: $6.01 USD 0.05 (0.84%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 139.11M
Revenue (ttm) n/a
Net Income (ttm) -33.01M
Shares Out 23.15M
EPS (ttm) -4.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $6.01
Previous Close $5.96
Change ($) 0.05
Change (%) 0.84%
Day's Open 6.23
Day's Range 6.01 - 6.23
Day's Volume 5,218
52-Week Range 4.52 - 11.50

More Stats

Market Cap 139.11M
Enterprise Value 69.52M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.15M
Float 17.08M
EPS (basic) -4.05
EPS (diluted) -4.05
FCF / Share -1.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 20,727
Short Ratio 2.77
Short % of Float 0.12%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.95
Revenue n/a
Operating Income -34.18M
Net Income -33.01M
Free Cash Flow -30.64M
Net Cash 69.59M
Net Cash / Share 3.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.89%
ROE -45.97%
ROIC -119.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(291.01% upside)
Current: $6.01
Target: 23.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-22.21-12.50-6.71-1.77
Net Income-20.56-12.72-6.43-1.90
Shares Outstanding5.622.001.971.96
Earnings Per Share-3.66-7.62-3.76-1.01
Operating Cash Flow-17.58-11.30-4.10-1.34
Capital Expenditures-1.31-0.14-0.85-0.10
Free Cash Flow-18.89-11.44-4.95-1.43
Cash & Equivalents82.4139.758.15-
Total Debt1.23---
Net Cash / Debt81.1839.758.15-
Book Value84.4642.8011.53-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BiomX, Inc.
Country Israel
Employees 73
CEO Jonathan Eithan Solomon

Stock Information

Ticker Symbol PHGE
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: PHGE


BiomX, a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.